Meczker Ágnes, Mikó Alexandra, Gede Noémi, Szentesi Andrea, Párniczky Andrea, Gódi Szilárd, Hegyi Péter
Division of Translational Medicine, First Department of Medicine, University of Pécs, Medical School.
Pancreas. 2019 Apr;48(4):488-495. doi: 10.1097/MPA.0000000000001297.
This study aimed to compare the clinical course of 5-aminosalicylic acid-derived, drug-induced acute pancreatitis (5-ASA-DIAP) to acute pancreatitis (AP) caused by other etiologies.
A cohort of patients with 5-ASA-DIAP was established through literature search. As a control AP (CAP) group, a cohort was generated from a registry. Data on the diagnostic procedure, symptoms, enzyme elevation, imaging, severity, and recovery parameters were collected. Causality was assessed using the Naranjo algorithm.
Twenty-nine articles were included, which describe 36 patients with fifty-one 5-ASA-DIAP episodes (60.78% female, 39.22% male). There were 88.2% mild, 3.92% moderate, and 7.84% severe cases of AP in the 5-ASA-DIAP group, and 70.6%, 25.5%, and 3.92% such cases in the CAP population, respectively. Symptoms improved significantly faster (mean ± SE, 2.5 ± 0.34 vs 3.74 ± 0.42 days; P = 0.018); however, pancreatic enzyme levels normalized significantly more slowly (6.27 ± 1.53 vs 3.63 ± 0.61 days, P = 0.008) in the 5-ASA-DIAP cohort compared with the CAP group. This study confirms that there are no diagnostic differences between 5-ASA-DIAP and AP of other etiologies.
Fewer moderate but more severe cases were found in the 5-ASA-DIAP group; therefore, 5-ASA-DIAP must be taken as seriously as AP of other etiologies.
本研究旨在比较5-氨基水杨酸所致药物性急性胰腺炎(5-ASA-DIAP)与其他病因引起的急性胰腺炎(AP)的临床病程。
通过文献检索建立5-ASA-DIAP患者队列。作为对照AP(CAP)组,从登记处生成一个队列。收集有关诊断程序、症状、酶升高、影像学、严重程度和恢复参数的数据。使用纳伦霍算法评估因果关系。
纳入29篇文章,描述了36例患者发生51次5-ASA-DIAP发作(女性占60.78%,男性占39.22%)。5-ASA-DIAP组中AP的轻度、中度和重度病例分别为88.2%、3.92%和7.84%,CAP人群中此类病例分别为70.6%、25.5%和3.92%。症状改善明显更快(均值±标准误,2.5±0.34天 vs 3.74±0.42天;P = 0.018);然而,与CAP组相比,5-ASA-DIAP队列中胰腺酶水平恢复正常明显更慢(6. – 27±1.53天 vs 3.63±0.61天,P = 0.008)。本研究证实5-ASA-DIAP与其他病因的AP之间在诊断上没有差异。
5-ASA-DIAP组中中度病例较少但重度病例较多;因此,必须像对待其他病因的AP一样认真对待5-ASA-DIAP。